REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle SocietyPRNewsWire • Tuesday
Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual SymposiumPRNewsWire • 08/30/23
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023PRNewsWire • 08/23/23
REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 08/02/23
REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare ConferencePRNewsWire • 08/01/23
REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 07/26/23
REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific MeetingPRNewsWire • 07/24/23
REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023PRNewsWire • 07/11/23
REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial UpdatesPRNewsWire • 06/27/23
REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement LawsuitPRNewsWire • 06/20/23
Regenxbio could be a gene therapy pioneer with multiple ways to win in 2023Proactive Investors • 06/02/23
REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter SyndromePRNewsWire • 05/23/23
REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023PRNewsWire • 05/22/23
REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical PortfolioPRNewsWire • 05/16/23
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 05/03/23
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual MeetingPRNewsWire • 05/02/23
REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 04/26/23
REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPRNewsWire • 04/18/23